Tavo Biotherapeutics is a biotechnology company developing investigational glaucoma and retinal treatments including TAV-001, an autonomic nervous system modulator.
Tavo Biotherapeutics secures **$17 million in Series A funding** led by Pureos Bioventures, with participation from Polaris Partners and Tau Capital. The capital will accelerate development of its pipeline of **novel therapies for glaucoma and retinal disease**. The company aims to expand its research and clinical progress in treating these eye conditions.
Tavo Biotherapeutics appoints **Lukas Scheibler, Ph.D.** as Chief Research and Development Officer and **Graham Cooper** as Chief Financial Officer. Both executives bring extensive industry experience to leadership roles at the biotherapeutics company. The appointments aim to strengthen Tavoβs drug development and financial strategy capabilities.